Septerna Inc (SEPN) Stock Price, Quote & News

Company Profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 338 3533

Website: septerna.com

Address:

250 East Grand Avenue, South San Francisco, United States

TheTradeXchange Apr. 13 at 12:00 PM

$SEPN - Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

0 · Reply

chole1 Apr. 10 at 7:59 PM

$SEPN High volume sell-off.. hope the Q2 P1 start for the PTH1R is all good.

0 · Reply

SuperGreenToday Apr. 7 at 9:36 PM

$SEPN Share Price: $24.84 Contract Selected: Oct 16, 2026 $32.0 Calls Buy Zone: $6.27 – $7.75 Target Zone: $10.41 – $12.72 Potential Upside: 57% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

erevnon Mar. 24 at 7:05 PM

JP Morgan maintains Septerna $SEPN at Overweight and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

LovePNW Mar. 11 at 7:50 PM

$SEPN https://www.marketbeat.com/instant-alerts/truist-financial-forecasts-strong-price-appreciation-for-septerna-nasdaqsepn-stock-2026-03-11/

0 · Reply

erevnon Mar. 11 at 2:43 PM

Truist Securities maintains Septerna $SEPN at Buy and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

shavitmi Mar. 6 at 1:57 PM

$TNYA if $ALNY a $40 bilion company works with TNYA i think its a home run $SEPN

0 · Reply

shavitmi Mar. 6 at 11:06 AM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

0 · Reply

shavitmi Mar. 5 at 8:26 PM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

1 · Reply

LovePNW Mar. 3 at 9:14 PM

$SEPN https://www.marketbeat.com/instant-alerts/wells-fargo-company-increases-septerna-nasdaqsepn-price-target-to-4800-2026-03-03/

0 · Reply

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Mar 9, 2026, 4:05 PM EDT - 5 weeks ago

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 1, 2026, 9:45 AM EST - 6 weeks ago

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Feb 24, 2026, 8:00 AM EST - 6 weeks ago

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Feb 10, 2026, 4:05 PM EST - 2 months ago

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 10, 2026, 8:00 AM EST - 2 months ago

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

Jan 8, 2026, 4:05 PM EST - 3 months ago

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

Dec 17, 2025, 8:00 AM EST - 4 months ago

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 4 months ago

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 5 months ago

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 8:00 AM EST - 5 months ago

Septerna to Participate in Upcoming Investor Conferences

Sep 29, 2025, 4:01 PM EDT - 7 months ago

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Aug 21, 2025, 8:00 AM EDT - 8 months ago

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Aug 11, 2025, 4:01 PM EDT - 8 months ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 2:30 PM EDT - 10 months ago

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

May 29, 2025, 8:00 AM EDT - 11 months ago

Septerna to Present at Jefferies Global Healthcare Conference

May 15, 2025, 4:01 PM EDT - 11 months ago

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

May 14, 2025, 9:43 AM EDT - 11 months ago

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

NVO

May 14, 2025, 7:31 AM EDT - 11 months ago

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

NVO

May 14, 2025, 7:04 AM EDT - 11 months ago

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

NVO

May 14, 2025, 6:59 AM EDT - 11 months ago

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 19, 2025, 10:32 AM EDT - 1 year ago

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Mar 6, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out

Mar 5, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation

Mar 4, 2025, 10:00 AM EST - 1 year ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 3, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Shareholders to Inquire about Securities Investigation

Mar 2, 2025, 10:00 AM EST - 1 year ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 28, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect

Feb 27, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Stockholders to Inquire about Securities Investigation

Feb 26, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Investors to Learn More About the Investigation

Feb 26, 2025, 8:00 AM EST - 1 year ago

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 10:00 AM EST - 1 year ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Stockholders to Learn More About the Investigation

Feb 21, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Feb 19, 2025, 2:00 PM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Feb 18, 2025, 4:15 PM EST - 1 year ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 8:00 AM EST - 1 year ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Dec 18, 2024, 8:00 AM EST - 1 year ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 1 year ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 19, 2024, 2:10 PM EST - 1 year ago

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Oct 30, 2024, 4:41 PM EDT - 1 year ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 25, 2024, 12:25 PM EDT - 1 year ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 24, 2024, 9:47 PM EDT - 1 year ago

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 8:11 AM EDT - 1 year ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

TheTradeXchange Apr. 13 at 12:00 PM

$SEPN - Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

0 · Reply

chole1 Apr. 10 at 7:59 PM

$SEPN High volume sell-off.. hope the Q2 P1 start for the PTH1R is all good.

0 · Reply

SuperGreenToday Apr. 7 at 9:36 PM

0 · Reply

erevnon Mar. 24 at 7:05 PM

JP Morgan maintains Septerna $SEPN at Overweight and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

LovePNW Mar. 11 at 7:50 PM

$SEPN https://www.marketbeat.com/instant-alerts/truist-financial-forecasts-strong-price-appreciation-for-septerna-nasdaqsepn-stock-2026-03-11/

0 · Reply

erevnon Mar. 11 at 2:43 PM

Truist Securities maintains Septerna $SEPN at Buy and raises the price target from $34 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

shavitmi Mar. 6 at 1:57 PM

$TNYA if $ALNY a $40 bilion company works with TNYA i think its a home run $SEPN

0 · Reply

shavitmi Mar. 6 at 11:06 AM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

0 · Reply

shavitmi Mar. 5 at 8:26 PM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

1 · Reply

LovePNW Mar. 3 at 9:14 PM

$SEPN https://www.marketbeat.com/instant-alerts/wells-fargo-company-increases-septerna-nasdaqsepn-price-target-to-4800-2026-03-03/

0 · Reply

IN0V8 Mar. 3 at 8:55 PM

$SEPN Buy Wells Fargo raises target price to $48 from $28

0 · Reply

erevnon Mar. 3 at 4:25 PM

Wells Fargo maintains Septerna $SEPN at Overweight and raises the price target from $28 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

AlertsAndNews Mar. 1 at 11:32 PM

$SEPN Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy "SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing" Conference call here tomorrow morning as well. "Company to Host Conference Call and Webcast on Monday, March 2, 2026, at 8:00 a.m. ET"

0 · Reply

BillionerOfKing Feb. 25 at 10:54 PM

$SEPN Current Stock Price: $29.99 Contracts to trade: $30.0 SEPN Mar 20 2026 Call Entry: $1.85 Exit: $3.42 ROI: 85% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

RaymondNorman877 Feb. 18 at 12:40 PM

$SEPN Rare-disease biotech with asymmetric upside; timeline slippage is main threat.

0 · Reply

OfficialStocktwitsUser Feb. 17 at 9:56 AM

$SEPN RSI: 56.86, MACD: 0.0744 Vol: 1.14, MA20: 25.62, MA50: 26.41 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BondHarbinger Feb. 4 at 2:24 PM

$SEPN is a clinical-stage biotech focused on rare diseases; its pipeline is in development, making it a high-risk, binary investment.

0 · Reply

BillionerOfKing Feb. 3 at 2:10 AM

$SEPN Current Stock Price: $25.09 Contracts to trade: $26.0 SEPN Feb 20 2026 Call Entry: $0.85 Exit: $1.52 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

GJ_Rockabilt Jan. 30 at 1:04 PM

$SEPN Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

SocioCobb Jan. 23 at 10:25 PM

$SEPN Kaboomalooma!

0 · Reply

IN0V8 Jan. 20 at 10:46 PM

$SEPN H.C. Wainwright raises target price to $35 from $30

0 · Reply

Market Cap	1.04B
Revenue (ttm)	45.95M
Net Income (ttm)	-48.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.38%
Debt to Equity Ratio	0.00

Volume	218,200
Avg Vol	297,814
Day's Range	N/A - N/A
Shares Out	44.91M
Stochastic %K	17%
Beta	3.50
Analysts	Strong Sell
Price Target	$44.43